The Life Sciences industry is under increasing pressure from governments, healthcare authorities and private insurers seeking to reduce costs and increase value of healthcare providers. Markets for healthcare products have become more strictly regulated, approvals of innovative products are increasingly hard won, and competition from generics and the East is fierce. These market conditions are impacting all aspects of Life Sciences businesses.
Tefen provides strategic consulting and works with Life Sciences companies across their value chains to transform sales, marketing, supply chain, manufacturing, quality and R&D. We help medical device, pharmaceutical and biomedical companies to define new commercial and operational strategies, then work closely with them to deliver major performance improvements.
Our recent work in the industry focuses on topics including pre-launch, pricing and positioning, customer segmentation, key account management, Lean Six Sigma manufacturing, supply chain optimization and risk management, QC efficiency, tech transfer and transforming R&D operations.
CDMOs assist biopharmaceutical companies in creating the process development and the manufacturing cycle from start to finish. What are the obstacles that stand in the way of CDMOs from scaling-up?
ExploreHow can a pharmaceutical company prepare for the day after its branded drug patent loss?
ExploreA Tefen article, describing the outstanding advantages of DfX in the Life Science industry, has been published in Medical Product Outsourcing Magazine
ExploreA major pharmaceutical manufacturer experienced a few issues that led to low ROI and lack of market confidence in this company
ExploreA pharmaceutical distribution company sought to initiate a Continuous Improvement program throughout their entire Distribution Center network, focusing on Quality, Efficiency, Self-sufficiency and Embedment of CI culture.
ExploreA worldwide developer, manufacturer and marketer of medical devices was experiencing a difficulty: a major business unit of the company was not able to respond to customer or governmental shifts
Explore